Cargando…
Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engine...
Autores principales: | Nettelbeck, Dirk M., Leber, Mathias F., Altomonte, Jennifer, Angelova, Assia, Beil, Julia, Berchtold, Susanne, Delic, Maike, Eberle, Jürgen, Ehrhardt, Anja, Engeland, Christine E., Fechner, Henry, Geletneky, Karsten, Goepfert, Katrin, Holm, Per Sonne, Kochanek, Stefan, Kreppel, Florian, Krutzke, Lea, Kühnel, Florian, Lang, Karl Sebastian, Marchini, Antonio, Moehler, Markus, Mühlebach, Michael D., Naumann, Ulrike, Nawroth, Roman, Nüesch, Jürg, Rommelaere, Jean, Lauer, Ulrich M., Ungerechts, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402873/ https://www.ncbi.nlm.nih.gov/pubmed/34452286 http://dx.doi.org/10.3390/v13081420 |
Ejemplares similares
-
Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014) -
Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
por: Angelova, Assia L., et al.
Publicado: (2015) -
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
por: Angelova, Assia L., et al.
Publicado: (2017) -
Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
por: Angelova, Assia L., et al.
Publicado: (2017) -
Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells
por: Angelova, Assia, et al.
Publicado: (2023)